ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

peginterferon alfa-2b

Also written as “Peginterferon alfa-2b”, “peginterferon alfa-2b (SCH 54031)” and “PEG-Intron”.

Its studies are mostly in Hepatitis C, Chronic · Hepatitis C · Hepatitis B, Chronic · Melanoma · Hepatitis B, led by 4 companies.

Drug pagePeginterferon alfa-2b: every studyAll 139 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 15, 200552 company-led studies, 2 open or runningNext primary completion: May 31, 2029

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only450 open or runningphase 4since Nov 15, 2005Mar 29, 2000none ahead
Tanabe Pharma30 open or runningphase 3since Nov 2, 2011Feb 24, 2008none ahead
Xiamen Amoytop Biotechits history only32 open or runningphase 3since Apr 12, 2021Apr 12, 2021May 31, 2029NCT06707922
FGK Clinical Researchits history only10 open or runningphase 4since Jul 11, 2006Jul 11, 2006none ahead

Also a collaborator on its studies: Vertex Pharmaceuticals, Integrated Therapeutics Group, Johnson & Johnson and ViroPharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tanabe Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2008First study: phase 1 study in Hepatitis CFirst studyNCT00630058 · 20 enrolled · Japan
  2. Nov 2, 20112 phase 3 studies in Hepatitis C, ChronicNCT01468584, NCT01466192

TargetBeta

“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
peginterferon alfa-2aruleHoffmann-La Rochephase 4100
Interferon beta-1aruleBiogenphase 460

Studies

All 3 Tanabe Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01468584Hepatitis C, Chronic · Japan3CompletedSep 201310
NCT01466192Hepatitis C, Chronic · Japan3CompletedAug 2013108
NCT00630058Hepatitis C · Japan1CompletedMar 200920

How it is read

Names in the registry

  • “Peginterferon alfa-2b”, 10 entries
  • “peginterferon alfa-2b (SCH 54031)”, 5 entries
  • “PEG-Intron”, 4 entries
  • “PegIntron (peginterferon alfa-2b)”, 4 entries
  • “Peginterferon alfa-2b injection”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.